Resources
About Us
Home Report
Store
Monoclonal Antibodies Market
Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type (Therapeutic, Research, Diagnostic) Application (Oncology, Immunology, Cardiology, Neurology), Source (Humanized, Murine, Human), Production, End User - Global Forecast to 2031
Report ID:MRHC - 1041246 Pages: 410 Jun-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursMonoclonal Antibodies Market Size & Forecast
The Monoclonal Antibodies Market is projected to reach $449.8 billion by 2031 at a CAGR of 11.2% from 2024 to 2031. The growth of this market is driven by the high burden of cancer and autoimmune diseases globally, increasing funding for clinical trials and research, growth in the biopharmaceutical industry, rising prevalence of infectious diseases, and increasing research in proteomics and genomics.
Furthermore, increasing R&D investments by pharmaceutical and biotech companies, expanding applications of antibodies in clinical trials and medical research, increasing research activities in developing countries, the rising need for new biomarker identification, and initiatives aimed at enhancing diagnostic testing are expected to create market growth opportunities.
Monoclonal Antibodies Market Growth Drivers
High Burden of Cancer and Autoimmune Diseases Globally
Cancer poses a major burden on the global population. For instance, the total number of new cancer cases is estimated to reach 24.6 million by 2030 from 19.3 million in 2020 (Source: International Agency for Research on Cancer). Monoclonal antibodies (mABs) are used for the treatment of cancer as mABs. These targeted drugs identify specific proteins and cancer cells and help in the inhibition of their growth.
Additionally, monoclonal antibodies are used to treat autoimmune diseases, a condition in which the body's immune system attacks its tissues, causing inflammation, damage to healthy tissues, and sometimes organ dysfunction. Several anti-inflammatory monoclonal antibodies are used in the treatment of autoimmune diseases. For instance, monoclonal antibodies used to treat arthritis are known as tumor necrosis factor (TNF) inhibitors. TNF is a protein involved in causing inflammation and damage of rheumatoid arthritis.
Growth in the Biopharmaceutical Industry
The market for biopharmaceuticals is increasing due to the increasing number of bio-approvals, companies’ rising emphasis on expanding biomanufacturing capacities, and government initiatives supporting bioproduction. In 2021, 5,500 new planned clinical trials have started, an increase of 14% from 2020 and 19% from 2019.
Government agencies worldwide are undertaking initiatives to support the growth of the biopharmaceutical market. For instance, the Chinese government has undertaken several initiatives for the development and commercialization of biosimilars. Countries like Malaysia, Indonesia, Thailand, and Taiwan have established regulatory pathways for biosimilars, increasing access to biosimilar technology. The growth in the biopharmaceutical industry is driving the development of monoclonal antibodies (mAbs). mAbs are regarded as one of the fastest-growing classes of biopharmaceuticals.
Click here to: Get Free Sample Pages of this Report
Monoclonal Antibodies Market Trends
Increasing Focus on Personalized Medicine
Personalized/precision medicine uses an individual’s genomic information to offer targeted treatments. As precision medicine is based on individuals’ genetic makeup, it can overcome the limitations of traditional medicines and provide effective treatment. Monoclonal antibody therapies have improved precision medicine by providing personalized treatment options and enabling targeted therapy. These antibodies can be tailored to precisely bind and recognize disease-associated molecules, such as viral antigens or tumor markers. This targeted approach helps in the development of personalized therapies designed for individual patients, minimizing side effects and maximizing treatment efficacy.
The rising funding in R&D of personalized medicines, key players’ focus on manufacturing personalized medicines, and growing approvals for personalized medicines are driving the growth of the monoclonal antibodies market. For instance, in 2022, the U.S. FDA approved 34% of personalized medicine among total FDA approvals, marking an increase from 25% in 2019.
Advancements in Antibody Engineering
Antibody engineering techniques have expanded and enhanced the application of monoclonal antibodies. Researchers can optimize and modify antibodies to improve their half-life, efficacy, and stability. Some of the advancements in antibody engineering include computational antibody design, phage display technology, single B cell sequencing, CRISPR/Cas9 technology, antibody-drug conjugates (ADCS) technology, humanized mouse models, high-throughput screening (HTS), and artificial intelligence & machine learning.
AI and machine learning are now increasingly used in antibody engineering to guide the design of novel antibody formats, optimize antibody sequences for improved properties, and tools to predict antibody-antigen interactions. These approaches are becoming more useful in discovering novel therapeutic targets and optimizing the antibody discovery process. Similarly, humanized mouse models, engineered to express human antibody repertoires, are used for monoclonal antibody discovery and development. These models help for the maturation of human antibodies and in vivo generation in response to antigen challenge, thus mimicking human immune response and reducing the chances of immunogenicity observed with murine-derived antibodies.
Monoclonal Antibodies Market Opportunity
Increasing R&D Investments by Pharmaceutical & Biotech Companies
Pharmaceutical and biotech companies are heavily investing in research and development with a focus on developing novel drugs, drug molecules, and biologics. For instance, according to the PhRMA (Pharmaceutical Research and Manufacturers of America) annual membership survey 2022, the R&D spending of PhRMA member companies in the U.S. pharmaceutical & biopharmaceutical sector reached USD 102.3 billion in 2021, a significant increase from USD 83.0 billion in 2019.
Additionally, according to PhRMA and the National Venture Capital Association, venture capital investments from established biopharmaceutical companies in emerging biotechnology firms in the U.S. to support R&D increased from USD 11 billion in 2015 to USD 15 billion in 2020.
Research & development aids in the identification and validation of new biologics, including monoclonal antibodies for therapeutic applications. Therefore, such investments in R&D are expected to lead to the development of new monoclonal antibodies, which will boost their production for therapeutic purposes.
Monoclonal Antibody Market Analysis: Key Findings
By Type: In 2024, the Therapeutic Monoclonal Antibodies Segment to Dominate the Monoclonal Antibodies Market
Based on type, the monoclonal antibodies market is segmented into research monoclonal antibodies, diagnostic monoclonal antibodies, and therapeutic monoclonal antibodies. In 2024, the therapeutic monoclonal antibodies segment is expected to account for the largest share of 90.2% of the monoclonal antibodies market. This segment’s large market share can be attributed to factors such as the wide range of applications of monoclonal antibodies in therapeutics for various diseases and conditions, the increasing prevalence of chronic diseases, and the growing focus of pharmaceutical and biopharmaceutical companies on the development of monoclonal antibody-based therapeutics. Furthermore, recent approvals for therapeutic monoclonal antibodies contribute to the growth of this segment. For instance, in August 2023, Regeneron Pharmaceuticals, Inc. (U.S.) received approval for Veopoz (pozelimab-bbfg) for the treatment of adult and pediatric patients one year of age and older with CHAPLE disease. Similarly, in August 2023, Pfizer Inc. (U.S.) received approval for ELREXFIO (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).
By Production Process: In 2024, the In Vitro Process Segment to Dominate the Monoclonal Antibodies Market
Based on production process, the monoclonal antibodies market is segmented into in vivo process and in vitro process. In 2024, the in vitro process segment is expected to account for the largest share of the monoclonal antibodies market. In vitro antibody production methods involve the use of recombinant technology, hybridoma cells, or mammalian cell culture to produce monoclonal antibodies. This segment's large market share can be attributed to benefits offered by in vitro production methods, including the production of specific antibody isotypes, the generation of antibodies with uniformity and high specificity, reduced reliance on mouse models through the use of humanized mouse models, and a reduced risk of immunogenicity.
By Source: In 2024, the Human Segment to Dominate the Monoclonal Antibodies Market
Based on source, the monoclonal antibodies market is segmented into human, humanized, murine, chimeric, and other sources. In 2024, the human segment is expected to account for the largest share of 33.2% of the monoclonal antibodies market. The increased utilization of human cell lines for monoclonal antibody production, which yields antibodies most similar to those naturally produced in the human body, is the primary factor contributing to the segment’s large market share. Furthermore, the increasing number of drug launches and product approvals for human monoclonal antibodies, enhanced efficacy, improved safety profiles, and the use of humanized animal models for the production of research & diagnostic monoclonal antibodies (MABs) contribute to this segment’s large market share.
By End User: In 2024, the Hospitals Segment to Dominate the Monoclonal Antibodies Market
Based on end user, the monoclonal antibodies market is segmented into pharmaceutical & biotechnology companies, hospitals, contract research organizations, and other end users. In 2024, the hospitals segment is expected to account for the largest share of the monoclonal antibodies market. This segment’s large market share can be attributed to the rising number of patient visits to hospitals seeking various treatments, including monoclonal antibody therapy, the availability of dedicated facilities for the administration of monoclonal antibody drugs and access to advanced technological resources, and the proliferation of hospitals offering monoclonal antibody therapy. For instance, starting in February 2022, Northern Arizona Healthcare (U.S.) began offering monoclonal antibody treatment for COVID-19 patients at no cost at dedicated facilities in Flagstaff and Cottonwood.
Geographical Analysis
North America to Dominate the Market in 2024
In 2024, North America is expected to account for the largest share of 34.9% of the monoclonal antibodies market. North America's significant market share can be attributed to various factors, including the increasing prevalence of target diseases such as cancer and cardiovascular diseases, the increasing funding allocated for the development of monoclonal antibodies, the presence of key market players in the region, the rising number of clinical trials for monoclonal antibodies, and favorable reimbursement policies. For instance, in June 2023, the Federal Emergency Management Agency (U.S.), an agency of the U.S. Department of Homeland Security, allocated USD 50 million as reimbursement to the Commonwealth of Massachusetts for the cost of delivering monoclonal antibody treatments to the public during the COVID-19 pandemic.
However, the market in Asia-Pacific is projected to register the highest growth rate of 13.4% during the forecast period. Countries in the region, including China, India, and South Korea, are expected to offer significant opportunities for market growth. The market growth in Asia-Pacific is driven by factors such as the expanding pharmaceutical and biotech industry, supportive government initiatives, the increasing number of clinical trials conducted in the region, and the rising demand for biologics to treat chronic and infectious diseases. Additionally, key players are ramping up production and receiving approvals for monoclonal antibody production in Asia Pacific countries, driven by the growing demand and usage in the region. For instance, in January 2024, AstraZeneca plc (U.K.) and Sanofi S.A. (France) received approval for Beyfortus (nirsevimab) in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants. Furthermore, in November 2023, Aragen Life Sciences (India) invested USD 30 million to establish a biologics manufacturing facility in India, focusing on the production of monoclonal antibodies, fusion proteins, and therapeutic proteins, thereby enhancing the company’s production capacity.
Monoclonal Antibodies Market: Key Companies
The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years (2020–2024). The key players operating in the global monoclonal antibodies market are Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Bristol-Myers Squibb (U.S.), GSK plc (U.K.), Merck KGaA (Germany), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Daiichi Sankyo Company (Japan), Biogen (U.S.), and Thermo Fisher Scientific Inc. (U.S.).
Monoclonal Antibodies Market Overview: Latest Developments from Key Industry Players
-
In March 2024, F. Hoffmann-La Roche AG (Switzerland) launched Vabysmo (faricimab), a bispecific monoclonal antibody, in India for the treatment of diabetic macular edema (DME) and neovascular or wet age-related macular degeneration (nAMD). With this launch, the company expanded its product portfolio in monoclonal antibodies for the ophthalmology therapeutic area.
-
In December 2023, KBI Biopharma, a JSR Life Sciences company (U.S.), launched SUREmAb, a MAB solution based on KBI’s SUREtechnology Platform designed for cost-efficient, safe, and optimized monoclonal antibody (mAb) manufacturing and development.
- In August 2023, Regeneron Pharmaceuticals, Inc. (U.S.) signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA) as a part of Project NextGen. This agreement aims to support the clinical development, manufacturing, and regulatory licensure process for a next-generation COVID-19 monoclonal antibody therapy for the prevention of SARS-CoV-2 infection.
- In June 2023, UCB (Belgium), a biopharmaceutical company, received U.S. FDA approval for RYSTIGGO (rozanolixizumab-noli) under Priority Review designation for the treatment of generalized myasthenia gravis (gMG) in adult patients. The approved antibody is a humanized IgG4 monoclonal antibody for subcutaneous infusion.
Monoclonal Antibody Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
410 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
11.2% |
|
Estimated Market Size (Value) |
$449.8 billion by 2031 |
|
Segments Covered |
By Type
By Production Process
By Source
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Belgium, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and the Middle East & Africa |
|
Key Companies |
The key players operating in the global monoclonal antibodies market are Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Bristol-Myers Squibb (U.S.), GSK plc (U.K.), Merck KGaA (Germany), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Daiichi Sankyo Company (Japan), Biogen (U.S.), and Thermo Fisher Scientific Inc. (U.S.) |
Key questions answered in the monoclonal antibodies market report:
The Monoclonal Antibodies Market focuses on therapeutic and diagnostic monoclonal antibodies, vital for treating diseases like cancer, autoimmune disorders, and infections, driven by advanced biopharmaceutical research.
The Monoclonal Antibodies Market is projected to reach approximately $449.8 billion by 2031, showcasing robust growth driven by increasing disease prevalence and advancements in antibody research and production.
The market is expected to grow at a CAGR of 11.2% from 2024 to 2031, driven by rising funding for clinical trials, increasing applications in medicine, and the demand for personalized therapies.
As of 2023, the Monoclonal Antibodies Market is valued significantly, with projections indicating it will expand to about $449.8 billion by 2031 due to increasing healthcare demands.
Key players include Novartis AG, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Amgen Inc., and Bristol-Myers Squibb, among others, leading in innovation and market presence.
The market trend is shifting towards personalized medicine, emphasizing precision therapies based on individual genetics, alongside advancements in antibody engineering and production techniques.
Major drivers include the high burden of cancer and autoimmune diseases, increased R&D funding, growth in the biopharmaceutical sector, and the rising demand for effective treatment options.
Segments include therapeutic, diagnostic, and research monoclonal antibodies; production processes (in vivo and in vitro); sources (human, humanized, murine); and end-users like hospitals and biotech companies.
The global outlook is positive, with substantial growth anticipated in North America and Asia-Pacific, driven by increasing investments, technological advancements, and a rising patient population needing innovative treatments.
The Monoclonal Antibodies Market is experiencing significant growth, projected to reach $449.8 billion by 2031, fueled by escalating investments in research and a growing patient base worldwide.
The market is projected to grow at a CAGR of 11.2% from 2024 to 2031, driven by the rising burden of diseases and advancements in therapeutic antibody development.
North America is expected to hold the highest market share in 2024, accounting for 34.9% of the market, driven by a high prevalence of diseases, significant R&D funding, and a strong pharmaceutical presence.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. High Burden of Cancer and Autoimmune Diseases Globally
4.2.2. Increasing Funding for Clinical Trials and Research
4.2.3. Growth in the Biopharmaceutical Industry
4.2.4. Rising Proteomics and Genomics Research Studies
4.2.5. Rising Prevalence of Infectious Diseases
4.3. Restraints
4.3.1. Availability of Alternative Diagnostic Tests
4.3.2. High Costs & Time Required for Antibody Development
4.4. Opportunities
4.4.1. Expanding Applications of Antibodies in Clinical Trials and Medical Research
4.4.2 Increasing Research Activities in Developing Countries
4.4.3. Increasing Need for New Biomarker Identification
4.4.4. Initiatives Aimed at Enhancing Diagnostic Testing
4.4.5. Increasing R&D Investments by Pharmaceutical & Biotech Companies
4.5. Challenges
4.5.1. Inaccuracy of Antibody Tests
4.5.2. High Manufacturing Costs
4.5.3. Concerns Regarding the Quality & Stability of Research Antibodies
4.5.4. Complexities in the Production Process
4.6. Factor Analysis
4.7. Trends
4.7.1. Increasing Focus on Personalized Medicine
4.7.2. Advancements in Antibody Engineering
4.7.3. Integration of Artificial Intelligence in Monoclonal Antibody Production
4.7.4. Use of Humanized Mouse Models
4.8. Regulatory Analysis
4.9. Pricing Analysis
4.10. Pipeline Analysis
4.11. Porter’s Five Force Analysis
5. Monoclonal Antibodies Market Assessment—by Type
5.1. Overview
5.2. Research Monoclonal Antibodies
5.2.1. Research Area
5.2.1.1. Oncology
5.2.1.2. Infectious Diseases
5.2.1.3. Cardiology
5.2.1.4. Immunology
5.2.1.5. Neurology
5.2.1.6. Stem Cell Research
5.2.1.7. Other Research Areas
5.2.2. Application
5.2.2.1. Proteomics
5.2.2.2. Drug Discovery & Development
5.2.2.3. Genomics
5.2.3. Technology
5.2.3.1. Flow Cytometry
5.2.3.2. Immunofluorescence
5.2.3.3. Enzyme-Linked Immunosorbent Assay
5.2.3.4. Multiplex Immunosorbent Assay
5.2.3.5. Western Blot
5.2.3.6. Immunohistochemistry
5.2.3.7. Immunoprecipitation (IP)
5.2.3.8. Other Research Technologies
5.3. Diagnostic Monoclonal Antibodies
5.3.1. Application
5.3.1.1. Oncology
5.3.1.2. Infectious Diseases
5.3.1.3. Pregnancy Detection/Fertility Testing
5.3.1.4. Cardiac Marker Testing
5.3.1.5. Other Diagnostic Applications
5.3.2. Technology
5.3.2.1. ELISA
5.3.2.2. Lateral Flow Assay
5.3.2.3. Immunohistochemistry (IHC)
5.3.2.4. Immunoprecipitation (IP)
5.3.2.5. Western Blot (WB)
5.3.2.6. Immunocytochemistry (ICC)
5.3.2.7. Other Diagnostic Technologies
5.4. Therapeutic Monoclonal Antibodies
5.4.1. Therapeutic Area
5.4.1.1. Oncology
5.4.1.2. Autoimmune Diseases
5.4.1.3. Neurological Diseases
5.4.1.4. Infectious Diseases
5.4.1.5. Other Therapeutic Areas
5.4.2. Route of Administration
5.4.2.1. Subcutaneous
5.4.2.2. Intravenous
6. Monoclonal Antibodies Market Assessment—by Production Process
6.1. Overview
6.2. In Vivo Process
6.3. In Vitro Process
6.3.1. Upstream Process
6.3.2. Downstream Process
7. Monoclonal Antibodies Market Assessment—by Source
7.1. Overview
7.2. Human
7.3. Humanized
7.4. Murine
7.5. Chimeric
7.6. Other Sources
8. Monoclonal Antibodies Market Assessment—by End User
8.1. Overview
8.2. Pharmaceutical & Biotechnology Companies
8.3. Hospitals
8.4. Contract Research Organizations (CROs)
8.5. Other End Users
9. Monoclonal Antibodies Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Switzerland
9.3.7. Belgium
9.3.8. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. South Korea
9.4.5. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America (RoLATAM)
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis/Market Ranking, by Key Players (2023)
11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)
11.1. Novartis AG
11.2. Pfizer Inc.
11.3. F. Hoffmann-La Roche AG
11.4. AbbVie Inc.
11.5. Amgen Inc.
11.6. Bristol-Myers Squibb
11.7. GSK plc
11.8. Merck KGaA
11.9. Eli Lilly and Company
11.10. AstraZeneca plc
11.11 Johnson & Johnson
11.12. Takeda Pharmaceutical Company Limited
11.13. Daiichi Sankyo Company
11.14. Biogen
11.15. Thermo Fisher Scientific Inc.
(Note: SWOT analysis of the top 5 companies will be provided.)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Global Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 2 Global Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 3 Global Research Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Global Research Monoclonal Antibodies Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 5 Global Research Monoclonal Antibodies Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 6 Global Research Monoclonal Antibodies Market for Cardiology, by Country/Region, 2022–2031 (USD Million)
Table 7 Global Research Monoclonal Antibodies Market for Immunology, by Country/Region, 2022–2031 (USD Million)
Table 8 Global Research Monoclonal Antibodies Market for Neurology, by Country/Region, 2022–2031 (USD Million)
Table 9 Global Research Monoclonal Antibodies Market for Stem Cell Research, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Research Monoclonal Antibodies Market for Other Research Areas, by Country/Region, 2022–2031 (USD Million)
Table 11 Global Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 12 Global Research Monoclonal Antibodies Market for Proteomics, by Country/Region, 2022–2031 (USD Million)
Table 13 Global Research Monoclonal Antibodies Market for Drug Discovery & Development, by Country/Region, 2022–2031 (USD Million)
Table 14 Global Research Monoclonal Antibodies Market for Genomics, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 16 Global Research Monoclonal Antibodies Market for Flow Cytometry, by Country/Region, 2022–2031 (USD Million)
Table 17 Global Research Monoclonal Antibodies Market for Immunofluorescence, by Country/Region, 2022–2031 (USD Million)
Table 18 Global Research Monoclonal Antibodies Market for Enzyme-Linked Immunosorbent Assay, by Country/Region, 2022–2031 (USD Million)
Table 19 Global Research Monoclonal Antibodies Market for Multiplex Immunosorbent Assay, by Country/Region, 2022–2031 (USD Million)
Table 20 Global Research Monoclonal Antibodies Market for Western Blot, by Country/Region, 2022–2031 (USD Million)
Table 21 Global Research Monoclonal Antibodies Market for Immunohistochemistry, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Research Monoclonal Antibodies Market for Immunoprecipitation (IP), by Country/Region, 2022–2031 (USD Million)
Table 23 Global Research Monoclonal Antibodies Market for Other Research Technologies, by Country/Region, 2022–2031 (USD Million)
Table 24 Global Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 25 Global Diagnostic Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 26 Global Diagnostic Monoclonal Antibodies Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Diagnostic Monoclonal Antibodies Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 28 Global Diagnostic Monoclonal Antibodies Market for Pregnancy Detection/Fertility Testing, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Diagnostic Monoclonal Antibodies Market for Cardiac Marker Testing, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Diagnostic Monoclonal Antibodies Market for Other Diagnostic Applications, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 32 Global Diagnostic Monoclonal Antibodies Market for ELISA, by Country/Region, 2022–2031 (USD Million)
Table 33 Global Diagnostic Monoclonal Antibodies Market for Lateral Flow Assay, by Country/Region, 2022–2031 (USD Million)
Table 34 Global Diagnostic Monoclonal Antibodies Market for Immunohistochemistry (IHC), by Country/Region, 2022–2031 (USD Million)
Table 35 Global Diagnostic Monoclonal Antibodies Market for Immunoprecipitation (IP), by Country/Region, 2022–2031 (USD Million)
Table 36 Global Diagnostic Monoclonal Antibodies Market for Western Blot (WB), by Country/Region, 2022–2031 (USD Million)
Table 37 Global Diagnostic Monoclonal Antibodies Market for Immunocytochemistry (ICC), by Country/Region, 2022–2031 (USD Million)
Table 38 Global Diagnostic Monoclonal Antibodies Market for Other Diagnostic Technologies, by Country/Region, 2022–2031 (USD Million)
Table 39 Global Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 40 Global Therapeutic Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 41 Global Therapeutic Monoclonal Antibodies Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 42 Global Therapeutic Monoclonal Antibodies Market for Autoimmune Diseases, by Country/Region, 2022–2031 (USD Million)
Table 43 Global Therapeutic Monoclonal Antibodies Market for Neurological Diseases, by Country/Region, 2022–2031 (USD Million)
Table 44 Global Therapeutic Monoclonal Antibodies Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 45 Global Therapeutic Monoclonal Antibodies Market for Other Therapeutic Areas, by Country/Region, 2022–2031 (USD Million)
Table 46 Global Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 47 Global Subcutaneous Therapeutic Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 48 Global Intravenous Therapeutic Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 49 Global Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 50 Global Monoclonal Antibodies Market for In Vivo Process, by Country/Region, 2022–2031 (USD Million)
Table 51 Global Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 52 Global Monoclonal Antibodies Market for In Vitro Process, by Country/Region, 2022–2031 (USD Million)
Table 53 Global Monoclonal Antibodies Market for Upstream Process, by Country/Region, 2022–2031 (USD Million)
Table 54 Global Monoclonal Antibodies Market for Downstream Process, by Country/Region, 2022–2031 (USD Million)
Table 55 Global Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 56 Global Human Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 57 Global Humanized Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 58 Global Murine Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 59 Global Chimeric Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 60 Global Monoclonal Antibodies Market for Other Sources, by Country/Region, 2022–2031 (USD Million)
Table 61 Global Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 62 Global Monoclonal Antibodies Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 63 Global Monoclonal Antibodies Market for Hospitals, by Country/Region, 2022–2031 (USD Million)
Table 64 Global Monoclonal Antibodies Market for Contract Research Organizations, by Country/Region, 2022–2031 (USD Million)
Table 65 Global Monoclonal Antibodies Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 66 Global Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 67 North America: Monoclonal Antibodies Market, by Country, 2022–2031 (USD Million)
Table 68 North America: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 69 North America: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 70 North America: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 71 North America: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 72 North America: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 73 North America: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 74 North America: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 75 North America: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 76 North America: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 77 North America: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 78 North America: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 79 North America: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 80 U.S.: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 81 U.S.: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 82 U.S.: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 83 U.S.: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 84 U.S.: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 85 U.S.: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 86 U.S.: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 87 U.S.: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 88 U.S.: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 89 U.S.: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 90 U.S.: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 91 U.S.: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 92 Canada: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 93 Canada: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 94 Canada: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 95 Canada: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 96 Canada: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 97 Canada: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 98 Canada: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 99 Canada: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 100 Canada: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 101 Canada: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 102 Canada: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 103 Canada: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 104 Europe: Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 105 Europe: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 106 Europe: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 107 Europe: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 108 Europe: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 109 Europe: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 110 Europe: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 111 Europe: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 112 Europe: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 113 Europe: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 114 Europe: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 115 Europe: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 116 Europe: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 117 Germany: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 118 Germany: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 119 Germany: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 120 Germany: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 121 Germany: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 122 Germany: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 123 Germany: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 124 Germany: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 125 Germany: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 126 Germany: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 127 Germany: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 128 Germany: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 129 France: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 130 France: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 131 France: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 132 France: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 133 France: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 134 France: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 135 France: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 136 France: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 137 France: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 138 France: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 139 France: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 140 France: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 141 U.K.: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 142 U.K.: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 143 U.K.: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 144 U.K.: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 145 U.K.: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 146 U.K.: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 147 U.K.: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 148 U.K.: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 149 U.K.: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 150 U.K.: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 151 U.K.: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 152 U.K.: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 153 Italy: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 154 Italy: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 155 Italy: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 156 Italy: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 157 Italy: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 158 Italy: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 159 Italy: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 160 Italy: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 161 Italy: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 162 Italy: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 163 Italy: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 164 Italy: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 165 Spain: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 166 Spain: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 167 Spain: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 168 Spain: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 169 Spain: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 170 Spain: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 171 Spain: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 172 Spain: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 173 Spain: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 174 Spain: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 175 Spain: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 176 Spain: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 177 Switzerland: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 178 Switzerland: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 179 Switzerland: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 180 Switzerland: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 181 Switzerland: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 182 Switzerland: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 183 Switzerland: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 184 Switzerland: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 185 Switzerland: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 186 Switzerland: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 187 Switzerland: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 188 Switzerland: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 189 Belgium: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 190 Belgium: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 191 Belgium: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 192 Belgium: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 193 Belgium: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 194 Belgium: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 195 Belgium: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 196 Belgium: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 197 Belgium: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 198 Belgium: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 199 Belgium: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 200 Belgium: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 201 Rest of Europe: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 202 Rest of Europe: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 203 Rest of Europe: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 204 Rest of Europe: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 205 Rest of Europe: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 206 Rest of Europe: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 207 Rest of Europe: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 208 Rest of Europe: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 209 Rest of Europe: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 210 Rest of Europe: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 211 Rest of Europe: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 212 Rest of Europe: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 213 Asia-Pacific: Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 214 Asia-Pacific: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 215 Asia-Pacific: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 216 Asia-Pacific: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 217 Asia-Pacific: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 218 Asia-Pacific: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 219 Asia-Pacific: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 220 Asia-Pacific: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 221 Asia-Pacific: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 222 Asia-Pacific: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 223 Asia-Pacific: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 224 Asia-Pacific: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 225 Asia-Pacific: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 226 China: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 227 China: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 228 China: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 229 China: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 230 China: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 231 China: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 232 China: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 233 China: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 234 China: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 235 China: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 236 China: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 237 China: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 238 Japan: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 239 Japan: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 240 Japan: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 241 Japan: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 242 Japan: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 243 Japan: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 244 Japan: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 245 Japan: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 246 Japan: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 247 Japan: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 248 Japan: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 249 Japan: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 250 India: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 251 India: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 252 India: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 253 India: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 254 India: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 255 India: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 256 India: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 257 India: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 258 India: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 259 India: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 260 India: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 261 India: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 262 South Korea: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 263 South Korea: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 264 South Korea: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 265 South Korea: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 266 South Korea: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 267 South Korea: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 268 South Korea: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 269 South Korea: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 270 South Korea: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 271 South Korea: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 272 South Korea: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 273 South Korea: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 274 Australia: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 275 Australia: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 276 Australia: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 277 Australia: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 278 Australia: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 279 Australia: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 280 Australia: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 281 Australia: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 282 Australia: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 283 Australia: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 284 Australia: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 285 Australia: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 286 Rest of Asia-Pacific: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 287 Rest of Asia-Pacific: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 288 Rest of Asia-Pacific: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 289 Rest of Asia-Pacific: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 290 Rest of Asia-Pacific: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 291 Rest of Asia-Pacific: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 292 Rest of Asia-Pacific: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 293 Rest of Asia-Pacific: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 294 Rest of Asia-Pacific: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 295 Rest of Asia-Pacific: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 296 Rest of Asia-Pacific: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 297 Rest of Asia-Pacific: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 298 Latin America: Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 299 Latin America: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 300 Latin America: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 301 Latin America: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 302 Latin America: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 303 Latin America: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 304 Latin America: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 305 Latin America: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 306 Latin America: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 307 Latin America: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 308 Latin America: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 309 Latin America: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 310 Latin America: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 311 Brazil: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 312 Brazil: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 313 Brazil: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 314 Brazil: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 315 Brazil: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 316 Brazil: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 317 Brazil: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 318 Brazil: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 319 Brazil: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 320 Brazil: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 321 Brazil: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 322 Brazil: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 323 Mexico: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 324 Mexico: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 325 Mexico: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 326 Mexico: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 327 Mexico: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 328 Mexico: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 329 Mexico: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 330 Mexico: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 331 Mexico: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 332 Mexico: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 333 Mexico: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 334 Mexico: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 335 Rest of Latin America: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 336 Rest of Latin America: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 337 Rest of Latin America: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 338 Rest of Latin America: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 339 Rest of Latin America: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 340 Rest of Latin America: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 341 Rest of Latin America: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 342 Rest of Latin America: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 343 Rest of Latin America: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 344 Rest of Latin America: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 345 Rest of Latin America: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 346 Rest of Latin America: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 347 Middle East & Africa: Monoclonal Antibodies Market, by Type, 2022–2031 (USD Million)
Table 348 Middle East & Africa: Research Monoclonal Antibodies Market, by Research Area, 2022–2031 (USD Million)
Table 349 Middle East & Africa: Research Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 350 Middle East & Africa: Research Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 351 Middle East & Africa: Diagnostic Monoclonal Antibodies Market, by Application, 2022–2031 (USD Million)
Table 352 Middle East & Africa: Diagnostic Monoclonal Antibodies Market, by Technology, 2022–2031 (USD Million)
Table 353 Middle East & Africa: Therapeutic Monoclonal Antibodies Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 354 Middle East & Africa: Therapeutic Monoclonal Antibodies Market, by Route of Administration, 2022–2031 (USD Million)
Table 355 Middle East & Africa: Monoclonal Antibodies Market, by Production Process, 2022–2031 (USD Million)
Table 356 Middle East & Africa: Monoclonal Antibodies Market for In Vitro Process, by Type, 2022–2031 (USD Million)
Table 357 Middle East & Africa: Monoclonal Antibodies Market, by Source, 2022–2031 (USD Million)
Table 358 Middle East & Africa: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 359 Recent Developments, by Company, 2020–2024
Table 360 Middle East & Africa: Monoclonal Antibodies Market, by End User, 2022–2031 (USD Million)
Table 361 Recent Developments, by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Monoclonal Antibodies Market, by Type, 2024 VS. 2031 (USD Million)
Figure 8 Global Monoclonal Antibodies Market, by Production Process, 2024 VS. 2031 (USD Million)
Figure 9 Global Monoclonal Antibodies Market, by Source, 2024 VS. 2031 (USD Million)
Figure 10 Global Monoclonal Antibodies Market, by End User, 2024 VS. 2031 (USD Million)
Figure 11 Global Monoclonal Antibodies Market, by Geography
Figure 12 Global Monoclonal Antibodies Market, by Type, 2024 VS. 2031 (USD Million)
Figure 13 Global Monoclonal Antibodies Market, by Production Process, 2024 VS. 2031 (USD Million)
Figure 14 Global Monoclonal Antibodies Market, by Source, 2024 VS. 2031 (USD Million)
Figure 15 Global Monoclonal Antibodies Market, by End User, 2024 VS. 2031 (USD Million)
Figure 16 Global Monoclonal Antibodies Market, by Geography, 2024 VS. 2031 (USD Million)
Figure 17 North America: Monoclonal Antibodies Market Snapshot
Figure 18 Europe: Monoclonal Antibodies Market Snapshot
Figure 19 Asia-Pacific: Monoclonal Antibodies Market Snapshot
Figure 20 Key Growth Strategies Adopted by Leading Players, 2020–2024
Figure 21 Global Monoclonal Antibodies Market: Competitive Benchmarking, by Type
Figure 22 Global Monoclonal Antibodies Market: Competitive Benchmarking, by Geography
Figure 23 Global Monoclonal Antibodies Market: Competitive Dashboard
Figure 24 Global Monoclonal Antibodies Market: Market Share Analysis/Market Ranking, By Key Players (2023)
Figure 25 Novartis AG: Financial Snapshot (2023)
Figure 26 Pfizer Inc.: Financial Snapshot (2023)
Figure 27 F. Hoffmann-La Roche AG: Financial Snapshot (2023)
Figure 28 AbbVie Inc.: Financial Snapshot (2023)
Figure 29 Amgen Inc.: Financial Snapshot (2023)
Figure 30 Bristol-Myers Squibb: Financial Snapshot (2023)
Figure 31 GSK plc: Financial Snapshot (2023)
Figure 32 Merck KGaA: Financial Snapshot (2023)
Figure 33 Eli Lilly and Company: Financial Snapshot (2023)
Figure 34 AstraZeneca plc: Financial Snapshot (2023)
Figure 35 Johnson & Johnson: Financial Snapshot (2023)
Figure 36 Takeda Pharmaceutical Company Limited: Financial Snapshot (2023)
Figure 37 Daiichi Sankyo Company: Financial Snapshot (2023)
Figure 38 Biogen: Financial Snapshot (2023)
Figure 39 Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Continuous Bioprocessing Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Mar-2024
IVD Reagents Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jul-2024
Cell Culture Media Market - Global Opportunity Analysis and Industry Forecast (2022-2029)
Published Date: Jul-2022
